On June 15, Hims & Hers Health rose 5.72% in regular trading, trading at $28.96/share, with turnover of $179 million.

On the news front, Goldman Sachs raised its global weight loss and obesity drug market forecast to $114 billion by 2030, up from a prior estimate of $101 billion. The revision was driven by accelerating adoption of oral GLP-1 drugs, stronger demand outside the U.S., and improved drug accessibility expanding the patient pool. Goldman Sachs also lifted its oral obesity drug sales estimate from $35 billion to $46 billion by 2030.

Meanwhile, recent sales tracking data showed positive year-over-year sales growth in three of the past four weeks, signaling clear marginal improvement in business fundamentals and reviving bullish sentiment. The company also recently completed its acquisition of Australian telehealth firm Eucalyptus, expanding its footprint into Australia, Canada, and Germany to consolidate its position as the largest global consumer health platform.

Hims & Hers Health operates a telehealth consultation platform connecting consumers to healthcare professionals for mental health, sexual health, dermatology, and primary care services.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)